According to the new market research report ” Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category – Forecasts to 2021 “, published by MarketsandMarkets™, The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.
Don’t miss out on business opportunities in Vaccine Adjuvants Market
Browse and in-depth TOC on “Vaccine Adjuvants Market”
90 – Tables
42 – Figures
156 – Pages
Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.
The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).
Value Addition for the Buyer:
This report aims to provide insights into the global vaccine adjuvants market. It provides valuable information on the product type, route of administration, disease type, applications, and application categories in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.
To know about the assumptions considered for the study, download the pdf brochure